Gene targeting approaches to complex genetic diseases: atherosclerosis and essential hypertension. by Smithies, O. & Maeda, N.
Proc. Natl. Acad. Sci. USA
Vol. 92, pp. 5266-5272, June 1995
Review
Gene targeting approaches to complex genetic diseases:
Atherosclerosis and essential hypertension
(animal models/gene disruption/gene duplication/quantitative traits)
Oliver Smithies and Nobuyo Maeda
Department of Pathology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7525
ABSTRACT Gene targeting allows
precise, predetermined changes to be
made in a chosen gene in the mouse
genome. To date, targeting has been used
most often for generation of animals com-
pletely lacking the product of a gene of
interest. The resulting "knockout" mice
have confirmed some hypotheses, have
upset others, but have rarely been unin-
formative. Models of several human ge-
netic diseases have been produced by tar-
geting-including Gaucher disease, cystic
fibrosis, and the fragile X syndrome.
These diseases are primarily determined
by defects in single genes, and their modes
of inheritance are well understood. When
the disease under study has a complex
etiology with multiple genetic and envi-
ronmental components, the generation of
animal models becomes more difficult but
no less valuable. The problems associated
with dissecting out the individual genetic
factors also increase substantially and the
distinction between causation and corre-
lation is often difficult. To prove causa-
tion in a complex system requires rigor-
ous adherence to the principle that the
experiments must allow detection of the
effects of changing only a single variable
at one time. Gene targeting experiments,
when properly designed, can test the ef-
fects of a precise genetic change com-
pletely free from the effects of differences
in any other genes (linked or unlinked to
the test gene). They therefore allow proofs
of causation.
Atherosclerosis and essential hyperten-
sion are two common diseases that ac-
count for a major portion of morbidity and
death in the United States. Although pop-
ulation studies have long suggested ge-
netic components in these complex dis-
eases, the details of their inheritance are
not well understood, in part because mul-
tiple factors are involved, both genetic and
environmental. A reasonable working hy-
pothesis is that these diseases in many
patients are the consequence of various
combinations of genetic defects that indi-
vidually may have only modest effects.
Gene targeting in mice provides a means
of testing this hypothesis. Individual genes
can be modified and their effects on the
development of atherosclerosis or on
blood pressures can be evaluated in a
manner that excludes the effects of any
other genes (linked or unlinked to the
target gene). The identification of com-
pensatory mechanisms induced by the pri-
mary gene modification can point to other
genes that antagonize the effects of the
target gene. Combinations of genetic
changes can then be made that allow the
detection of synergistic or antagonistic
interactions. In addition, at any stage of
the genetic investigations, the effects of
environmental factors such as high cho-
lesterol and fat or salt in the diet can be
evaluated, so that the interactions be-
tween environment and genotype can be
assessed. In what follows, we describe our
experiences while using gene targeting to
study the genetics of atherosclerosis and
hypertension, and some of the challenges
encountered, in order to illustrate how
such experiments can generate useful an-
imal models for further study and develop
an increased understanding of complex
genetic diseases.
Atherosclerosis
Atherosclerosis in humans is character-
ized by the development of intraarterial
lesions that may eventually become occlu-
sive (1). The earliest recognizable stage is
the preatherosclerotic "fatty streak" in
which an aggregation of lipid-rich macro-
phages can be found in the intima, be-
neath the endothelial lining of the vessels.
Fatty streaks progress to intermediate le-
sions that have smooth muscle prolifera-
tion as well as fatty components. Mature
lesions typically have fibrous caps and an
acellular lipid core and may develop re-
gions of calcification. Plaque fissuring fol-
lowed by thrombosis may eventually oc-
cur. Of numerous risk factors that have
been associated with atherosclerosis,
plasma lipoprotein levels are the best stud-
ied. Elevated levels of low density lipopro-
tein (LDL) and reduced levels of high
density lipoprotein (HDL) in plasma are
correlated with a higher risk for athero-
sclerosis in humans (2).
No mouse strains are known in which
atherosclerosis occurs spontaneously
when they are fed regular mouse chow
(4.5% fat/0.02% cholesterol). However,
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experiments by Paigen and her collabora-
tors (3) have shown that some inbred
strains develop vascular lesions when fed a
high fat (15.8%)/high cholesterol (1.25%)
diet. But the lesions, even in a susceptible
strain such as C57BL/6J (B6), rarely
progress beyond the fatty streak stage.
Mice naturally have high plasma levels of
HDL and low levels of LDL, conditions
that in humans are protective against ath-
erosclerosis. Mice also lack lipoprotein(a),
an atherogenic lipoprotein, and their lev-
els of cholesteryl ester transfer protein are
extremely low; both these proteins are
present in humans. Despite these differ-
ences, the general pathways of lipid trans-
port and metabolism in mice and humans
are otherwise so similar that one could
reasonably expect derangements in spe-
cific parts of the pathways to have similar
effects in the two species. Nevertheless,
when we began our gene targeting exper-
iments in mice, we expected that fully
developed atherosclerosis might not be
achievable without combining several de-
fects.
A series of targets were initially cho-
sen. The first gene (Apoe) codes for
apolipoprotein E (apoE), which plays a
central role in hepatic clearance from the
circulation of chylomicron remnants and
very low density lipoprotein remnants.
The second gene (Apoal) codes for apo-
lipoprotein A-I (apoA-I), which is the
major protein component of HDL. Dis-
ruption of theApoe gene was expected to
abolish apoE-mediated clearance and
therefore lead to an increase in the tran-
sit times of lipid in the circulation and to
hypercholesterolemia. Removal of
apoA-I was expected to cause a reduc-
tion in plasma HDL. Because of our
uncertainty that atherosclerosis would
occur consequent to these primary
changes in mice, targeted changes in
several other genes were also initiated,
including those coding for apoB, apo-
CIII, and hepatic lipase.
Abbreviations: ACE, angiotensin-converting
enzyme; AGT, angiotensinogen; apo, apoli-
poprotein; HDL, high density lipoprotein;
LDL, low density lipoprotein; ANP, atrial na-
triuretic peptide; ES cell, embryonic stem cell.
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ApoE-Deficient Mice Develop Athero-
sclerosis Spontaneously. Disruption of
the Apoe gene by us (4) and by Plump and
his collaborators at the Rockefeller Uni-
versity (5), in practice, proved by itself to
be sufficient to generate a mouse strain in
which mature atherosclerotic lesions de-
velop spontaneously. Homozygotes for
the disrupted Apoe gene (-/-) have se-
vere hypercholesterolemia (4-5 times nor-
mal levels); they develop atherosclerosis
on normal mouse chow, which is low in fat
and cholesterol; and their lesions progress
to a complex form (Fig. 1) that is essen-
tially identical to that seen in human pa-
tients (6, 7).
The regularity with which advanced ath-
erosclerosis develops spontaneously in the
apoE-deficient mice raises at least two
questions. First, is apoE deficiency as such
important in the etiology of the human
disease? Second, is the mouse model of
the disease made by this single mutation
relevant to the disease in humans, which
has a complex genetic etiology? An an-
swer to the first question is that it is very
unlikely that an appreciable proportion of
patients have atherosclerosis because of a
complete absence of apoE, since only
three families have been described with
such an absence (8-10). However, the
phenotype in mice does not depend on
complete absence of apoE. Thus, when
mice heterozygous (+/-) for the Apoe
gene disruption were fed the high fat/high
cholesterol diet for 3 months, 9/9 devel-
oped lesions. Most of the lesions were
fatty streaks, but fibrous cap formation
was seen in the heterozygote that had the
largest lesion. Only 3/9 wild-type (Apoe
+/+) animals fed the diet had lesions,
which averaged -1/10th the size of those
in the heterozygous animals; none were
complex (11). van Ree et al (12) have also
studied heterozygous mice (Apoe +/-)
and have demonstrated diet-induced hy-
percholesterolemia and atherosclerosis in
them. A hypothesis stemming from these
findings is that genetic reduction in apoE
levels in humans may constitute a risk
factor for atherogenesis, particularly un-
der dietary stress.
The second question, concerning the
relevance of the mouse condition gener-
ated by mutation of a single gene to the
human disease, which is genetically com-
plex, can be addressed by comparing the
lesions seen under various circumstances.
As described above, the complex lesions in
the apoE-deficient mice are very like the
complex lesions seen in humans. Similarly,
atherosclerotic lesions that occur sponta-
neously in pigs having one particular poly-
morphic form of the apolipoprotein con-
stituent of LDL (apoB) (13) are also very
similar in histology to human lesions.
Likewise, the lesions that occur in Wa-
tanabe heritable hyperlipidemic rabbits as
a consequence of a defect in the gene
coding for the LDL receptor (14) are
comparable to the human lesions. Finally,
in mice homozygous for a disrupted LDL
receptor gene (15) the lesions are again of
the same type, although a high fat diet is
required for their development (16). The
apoE-deficient mice consequently provide
a source of animals that, on a normal diet,
rapidly and regularly develop atheroscle-
rotic lesions of an advanced and appar-
ently general type that is common to many
species (including humans) independent
of the specific genetic etiology. This highly
reproducible phenotype is now being used
to investigate the effects of other genetic
modifications, drug treatments, dietary
factors, and the like.
Some differences in the detailed effects
of a targeted mutation in mice and of a
comparable mutation in humans are nev-
ertheless to be expected and may be very
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FIG. 1. A complex atherosclerotic lesion in the aorta of a 60-week-oldApoe -/- mouse fed
regular mouse chow. a, Calcified region; b, fibrous cap; c, acellular lipid core with cholesterol
crystal clefts; d, smooth muscle cells infiltrated with lipid. (x60.)
informative. For example, vascular occlu-
sions in human patients with advanced
atherosclerosis are frequently the conse-
quence of thrombosis initiated by plaque
fissuring, which exposes extracellular de-
bris to the clotting system. No evidence of
thrombotic incidents or sequelae has been
reported in the ApoE-deficient mice. This
suggests the presence in the mouse of
protective factors or the absence of dele-
terious factors present in humans. Identi-
fication of such factors would be of con-
siderable interest.
Effects of Other Gene Modifications on
Atherogenesis. Thanks to the pioneering
work of Brown and Goldstein on familial
hypercholesterolemia (17), defects in the
gene coding for the LDL receptor are the
best documented genetic causes of prema-
ture atherosclerosis and coronary heart
disease in humans. It was therefore to
some degree unexpected that mice lacking
the LDL receptor, generated by Ishibashi
et al (15), had only mild pathological
manifestations when fed normal mouse
chow, with only about twice normal levels
of plasma cholesterol. Severe lesions were,
however, seen when the mice were fed an
atherogenic diet (16). This result is in
contrast to humans with familial hyper-
cholesterolemia due to lack of the LDL
receptor; homozygous humans with this
condition can have >5 times normal
plasma cholesterol and develop severe
atherosclerosis even in childhood.
Although they are contributing substan-
tially to our understanding of factors that
modulate lipid metabolism, none of the
other single gene defects so far tested have
had such a dramatic effect on atherogen-
esis as the apoE deficiency or absence of
the LDL receptor. For example, as we had
expected, gene-targeted mice lacking
apoA-I have reduced HDL cholesterol
levels (about one-fourth normal). In hu-
mans, lower levels ofHDL cholesterol are
associated with a higher risk of athero-
sclerosis. We were therefore somewhat
surprised to find that mice having reduced
levels of HDL cholesterol caused by
apoA-I deficiency do not develop athero-
sclerotic lesions on normal chow and are
no more susceptible than wild-type ani-
mals to diet-induced atherosclerosis (18).
However, this finding agrees with reports
that some human individuals with muta-
tions in theAPOAl gene that cause severe
reductions in HDL cholesterol do not
appear to have an increased risk of coro-
nary artery disease (19). Thus, reduction
of HDL cholesterol is most likely not
sufficient to cause atherosclerosis by itself.
Combining Mutations. The success of
Apoe gene disruption in generating severe
atherosclerosis in the mouse is allowing
new ways of studying the genetic complex-
ity of atherogenesis. Thus, we and others
have begun to determine how mutations
in second or third genes modify the inci-
dence and progression of the disease gen-
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erated by the Apoe gene mutation. Pub-
lished accounts of this type of experiment
now include the protective effects on the
disease of genetically increasing the levels
of apoA-I (20, 21). The results show that
increased levels of apoA-I synthesis me-
diated by a human APOA1 transgene
cause a 2- to 3-fold increase in HDL and
a highly significant reduction in the inci-
dence and size of the atherosclerotic le-
sions. In a similar fashion, ApoE-deficient
mice are allowing evaluation of the roles
of various other genetic factors involved in
the detailed pathology of atherosclerosis
at the level of the arterial wall, such as
factors regulating smooth muscle prolifer-
ation and inflammation.
The combination in mice of two genetic
manipulations, one producing a serious
and complex disease and the other at-
tempting to ameliorate its severity, is
likely to be a powerful tool for investigat-
ing potential modes of gene therapy.
When a human disease is the consequence
of a known defect in a specific gene, the
first choice for gene therapy is likely to be
replacement of the defective gene func-
tion. When the disease is caused by defects
in more than one gene, as is probably the
case in human patients with atherosclero-
sis or essential hypertension, gene therapy
by replacement is less practical. The pos-
sibility that effective therapy can be
achieved by increasing the product of a
gene (such asApoal) that is not itself the
cause of the disease is therefore exciting.
The apoE-deficient mouse provides a
good model on which to test this type of
"generic" therapy. Conceivably, therapies
aimed at simultaneously increasing or de-
creasing production of several proteins
might also be used in the future for the
treatment of complex multifactorial disease.
Essential Hypertension
Essential hypertension (elevated blood
pressure not associated with a recogniz-
able predisposing condition) like athero-
sclerosis has a complex etiology, with ge-
netic factors being responsible for about
two-thirds of the familial aggregation of
blood pressures and with transmission of
cultural factors being responsible for the
remaining one-third (22). Normal blood
pressures are maintained by several inter-
acting systems that control cardiac output,
peripheral resistance, blood volume, renal
function, and sodium balance. The renin/
angiotensin system is one of these systems,
and it is intimately concerned with the
control of systemic and intrarenal blood
pressures and sodium retention. Its rele-
vance to essential hypertension is exem-
plified by the use of inhibitors of elements
of the system to treat hypertension. Cap-
topril and other orally active inhibitors of
the angiotensin-converting enzyme
(ACE), which converts the inactive pep-
tide angiotensin I to the hypertensive pep-
tide angiotensin II, are among the earliest
and most successful. Losartan (DuP753),
an orally active inhibitor of type 1 recep-
tors for angiotensin II, is one of the most
recent to undergo clinical trial. Virtually
all the genes coding for elements in the
renin/angiotensin system are conse-
quently a priori candidates for involve-
ment in hypertension.
Recent advances in the mapping of
genes that affect complex phenotypes pro-
vide a second reason for selecting the
renin/angiotensin system as a source of
candidate genes. For example, analyses of
crosses between spontaneously hyperten-
sive stroke-prone rats and wild-type Wist-
ar-Kyoto rats have shown that a genetic
determinant of the blood pressure of an-
imals fed a high-salt diet segregates with a
chromosomal region known to include the
gene coding forACE (23, 24). Similarly, in
humans, a specific variant (M235T) of the
gene coding for angiotensinogen (AGT),
which is the protein precursor of angio-
tensin I, has been found to segregate with
hypertension in a sibling pair study (25).
The variant was also associated with mod-
estly elevated (120% normal) plasma
AGT levels.
Linkage experiments must, however, be
interpreted with caution. Although they
demonstrate a genetic correlation (link-
age) between the phenotype and the
scored genetic variant(s), they do not in
themselves prove a causative relationship
between the two. In particular, they do not
exclude the possibility that the significant
factor is a difference in some other gene
linked to the scored variant, which itself
may be a neutral marker.
Gene Titration. Some of the problems
associated with proving causation can be
illustrated by describing gene targeting
experiments initially aimed at determin-
ing whether the AGT variant M235T can
cause hypertension in the mouse. Inspec-
tion of the published amino acid se-
quences of human AGT and mouse AGT
quickly showed that position 235 is in a
poorly conserved region of the protein. A








substitution cannot therefore be made in
the mouse. In its place, we decided to test
the broader hypothesis advanced by Jeune-
maitre et al (25)-namely, that the in-
creased level of plasma AGT associated
with the variant allele was the true cause
of the hypertension.
To test whether variants of the mouse
Agt gene that directly affect plasma AGT
levels also affect blood pressure, a two-
part targeting strategy was used to gener-
ate animals with plasma AGT levels rang-
ing from 0 to "145% normal levels. The
strategy includes conventional gene tar-
geting to produce a disrupted Agt gene
(26) and a special form of gap-repair gene
targeting to duplicate a wild-typeAgt gene
at its normal chromosomal location to-
gether with known or suspected control-
ling elements (27). Suitable breeding of
chimeras and F1 progeny derived from the
targeted embryonic stem (ES) cells al-
lowed generation of animals having 0, 1, 2,
3, or 4 copies of the wild-type gene. These
animals had a highly satisfactory grada-
tion of the steady-state plasma AGT lev-
els, which spanned the relative levels seen
in the human patients (Fig. 2). This
method of gene titration is applicable in
principle to any gene and should provide
a valuable tool for analyzing quantitative
genetic traits by experiments in mice.
Blood pressure measurements were
made on F2 mice having the genetically
controlled gradations in plasma AGT lev-
els. A highly significant increase in blood
pressures with increasing numbers of
functional Agt genes was observed, as il-
lustrated in Fig. 3.
When an experiment involves more
than one strain of mice, data from F2
animals must be interpreted with caution
because of possible effects from strain
differences (see below). In ourAgt exper-
iments, these effects were avoided by com-
paring F2 one-copy and three-copy ani-
mals, as is also discussed in more detail
below. In this way, we were able to estab-
lish a direct causal relationship between
Agt genotypes and blood pressures inde-
pendent of any other linked or unlinked
145±5
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FIG. 2. Effect ofAgt gene copy number on plasma AGT concentration relative to a normal
value of 100%. Data for 1, 2, and 3 gene copies are from F1 animals; data for 0 and 4 copies are
from F2 animals, the two-copy (wild type) mean value is assumed to be 100%.
Proc. Natl. Acad. Sci. USA 92 (1995)
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FIG. 3. Intraarterial blood pressures measured on 22 conscious and unrestrained F2 animals
having 1-4 functional copies of the Agt gene.
genetic differences and in animals with all
their normal compensatory mechanisms
intact.
Our results with the Agt system differ
somewhat from those of Tanimoto et at
(28). They also disrupted theAgt gene but
did not observe blood pressure differences
between their heterozygous and wild-type
mice. The investigators used ES cells de-
rived from a B6/CBA F1 embryo, and they
mated their chimeras to outbred ICR an-
imals. The genetic heterogeneity intro-
duced into the experiment by these
choices might have made the detection of
heterozygous effects more difficult (see
below).
Compensatory Changes Can Point to
Other Candidate Genes. Inspection of Fig.
2 shows that single-copy F1 animals het-
erozygous for a wild-type and disrupted
Agt gene have a steady-state plasma AGT
concentration (35% of normal), which is
less than the 50% level that might be
expected from their genotype. A simple
hypothesis which would explain this find-
ing is that pressure-sensing elements in the
kidney, in attempting to restore the blood
pressures of these heterozygotes to nor-
mal, increase the output of renin from the
kidney, thereby increasing the proportion
of plasma AGT converted to angiotensin
I (renin generates angiotensin I from
AGT) and thence through the action of
ACE to angiotensin II. This hypothesis
receives support from the finding that
plasma renin activity in these animals is
-2.5 times normal. Thus, one may rea-
sonably anticipate that genetic changes in
renin expression will also prove to influ-
ence resting blood pressures. As described
below, preliminary evidence from other
targeting experiments points in the same
direction.
Other Genes in the Renin/Angiotensin
System. We have tested two other genes in
the renin/angiotensin system by gene tar-
geting for their possible roles in the ge-
netic control of blood pressures. One is
theAce gene, which encodes two forms of
ACE-a somatic form present in the
plasma and throughout the body and a
testis form, which is specific to the testis
and therefore to males. The Ace gene was
disrupted in such a way that neither form
of the enzyme could be synthesized from
the targeted gene (29). Data from these
experiments showed a highly intriguing
result. Heterozygosity for disruption of
theAce gene (+/-) decreases the level of
serum ACE to approximately the same
extent in male and female F1 mice (to 75%.
and 66% of normal, respectively). How-
ever, the blood pressures of the F1 males
are decreased (by 16-21 mmHg), but the
blood pressures of the F1 females are not
decreased. (The use of F1 animals ensures
that the observed differences are solely
due to the targeted mutation.) In addition,
the breeding data showed that homozy-
gosity for disruption of the Ace gene af-
fects the fertility of males but not of
females. These observations suggest the
need for further investigation of the effects
of gender and the ACE gene on reproduc-
tion and blood pressure regulation.
Two main types of receptors for angio-
tensin II (the active peptide of the renin/
angiotensin system) have been described:
type 1 receptors, defined by their affinity
for DuP753 (Losartan); and type 2, de-
fined by their affinity for PD 123177. The
type 1 receptors have been subdivided into
two subtypes, lA and iB, which differ in
their sequences and are encoded by sep-
arate genes. Mice homozygous for a dis-
ruption of the gene (Agtrla) coding for the
type lA receptor have virtually no pressor
response to an intravenous injection of
angiotensin II (30). Both male and female
F2 heterozygotes (+/-) show a decrease
in blood pressures of -12 mmHg relative
to wild-type F2 (+/+) animals. Suitable
control experiments showed that this low-
ering of blood pressure in the heterozy-
gous mutants is independent of any ge-
netic differences between the strains of
mice used. Thus, all three genes in the
renin/angiotensin systems that have been
modified by gene targeting can directly
cause changes in resting blood pressure.
Unexpected phenotypes were seen in
two of the homozygous mutants. The Agt
null and Ace null animals share an inter-
esting kidney pathology characterized by a
generalized thinning of the cortex, with
focal areas of severe atrophy (26, 29). An
unexpected thickening, in some cases to
near occlusion, is observed in the walls of
many small arteries in the kidney, but not
elsewhere, and may be the primary defect.
Interestingly, animals lacking the type lA
angiotensin II receptor survive well and
do not show these abnormalities (30).
Genes in Other Blood Pressure Regu-
lating Systems. Many of the actions of
angiotensin II are antagonized by the
atrial natriuretic peptide (ANP), a peptide
produced primarily in the cardiac atria.
Genetic factors leading to a decrease in
ANP function are consequently also can-
didate causes of hypertension. We there-
fore generated mice with a targeted dis-
ruption of the gene (proANP) coding for
the precursor of ANP, again with ES cells
derived from strain 129 and with subse-
quent breeding of chimeras to strain B6
mates (31). Mutant F2 heterozygotes
(+/-) had atrial ANP levels close to half
those of wild-type F2 (+/+) animals.
However, neither the circulating ANP lev-
els nor the intraarterial blood pressures of
the (+/-) and (+/+) animals differed
significantly when they were fed regular
mouse chow (0.5% NaCl). On the other
hand, when the animals were fed a high-
salt diet (8% NaCl) for 2 weeks, the blood
pressures of the F, heterozygotes in-
creased significantly (P < 0.01) from 118
mmHg on normal chow to 146 mmHg on
the high-salt diet, while the blood pres-
sures of the wild-type F1 mice were un-
changed by the diet. Again, the use of F,
animals ensures that the observed differ-
ences are solely due to the targeted mu-
tation. These experiments consequently
establish that genetically reduced ANP
can cause salt-sensitive hypertension.
An interesting, although unexpected,
effect of disrupting the endothelin 1 gene
by targeting has been reported by Kuri-
hara et at (32). Endothelin 1 is a 21-amino
acid vasoconstrictive peptide. Homozy-
gous mutants (-/-) died at birth conse-
quent to craniofacial defects. Conscious
and unrestrained heterozygotes (+/-)
had mean intraarterial blood pressures
(116 mmHg) -11 mmHg above the pres-
sures (105 mmHg) of their wild-type lit-
termates. The observation that a genetic
reduction of endothelin 1 levels (to -60%
normal in the lungs of the heterozygotes)
caused an increase in blood pressure was
unexpected because of the known pressor
effects of the endothelin 1 peptide.
Experimental Considerations
The Choice of Proper Controls. In car-
rying out gene targeting, most investiga-
tors including ourselves start with ES cells
derived from inbred strain 129. The ideal
way to ensure that the observed pheno-
types are due solely to the targeted gene
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between the animals under study is to
breed the chimeras to mates of the same
inbred strain 129. We therefore regularly
do this to ensure the future availability of
the targeted mutation in the inbred strain
129 background. Unfortunately, confining
all subsequent breeding to strain 129 is
impractical if many animals are required
because of the poor breeding characteris-
tics of the strain and its susceptibility to
infection. These problems point to the
need for easily targetable ES cells from
inbred strains that are more fecund and
hardy than strain 129.
In practice, as described above, we nor-
mally mate the chimeras generated from
inbred strain 129-targeted ES cells to an-
other inbred strain, typically B6, to obtain
first generation progeny (F1). (Heterozy-
gotes obtained from breeding the chime-
ras to strain 129 mates can be used for this
purpose when chimeras cease to be avail-
able.) These hybrid F1 animals are vigor-
ous and fecund, and the animals of each
sex are genetically identical except for the
gene (wild type or targeted) they receive
from the strain 129-derived ES cell. Com-
parisons between wild-type (+ chromo-
some from B6/+ chromosome from 129)
and heterozygous (+ chromosome from
B6/targeted chromosome from 129) F1
animals therefore provide a test of the
effects of targeted modifications on the
phenotype of interest completely free
from any genetic heterogeneity intro-
duced by the use of two strains (Fig. 4).
Effect of Genes Unlinked to the Tar-
geted Locus. Proceeding to the F2 gener-
ation by intercrossing F1 +/- animals
makes it necessary to consider the effects
on the phenotype of differences between
the two parental strains at loci other than
the target locus. Any genes that differ
between the two strains and are not linked
to the target locus will in general segre-
gate randomly within F2 animals. If any of
these unlinked differences affect blood
pressure, for example, they will increase
the spread of blood pressures observed in
different animals, even though they have
identical genotypes at the target locus.
Differences in unlinked genes conse-
quently make it more difficult to detect
subtle effects of the targeted gene, al-
though they do not affect the average
magnitude of the effect.
Experiments with the proANP locus il-
lustrate how this spread of the phenotype
in F2 animals can be used in an advanta-
geous way to identify other genes likely to
be important. Some strains of mice (in-
cluding B6) naturally have one copy per
haploid genome of a gene that codes for
renin; other strains (including strain 129)
naturally have two renin genes per haploid
genome (33, 34). The renin locus Ren is
not linked to the proANP locus. Typing
animals in the proANP targeting experi-
ment for Ren genotypes showed that those
F2 animals that by chance received both
p
Fl
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FIG. 4. Cosegregation of strain-specific chromosomal regions and the target locus influences
experimental design and the choice of controls when two inbred strains are used in the breeding.
Comparison of F1 animals, wild-type A and mutant heterozygote B, allows assessment of the
effects of the targeted mutation free from biases due to any genetic differences between the two
strains. Note that there are three classes of F2 wild-type animals (C, D, and E) and two classes
of F2 heterozygotes (F and G), which can all be distinguished in ways that are discussed in the
text. Comparison of the three classes of F2 wild-type animals allows assessment of the effects on
the trait of interest of any naturally occurring strain differences at the target locus or in any genes
linked to it. Wild-type animal D is an excellent control for the mutant heterozygote F, as is
wild-type animal E for the mutant heterozygote G and for the mutant homozygote H. Effects of
strain differences in linked genes could be avoided in future generations if only class E, G, and
H animals are mated. P, parental animals: usually a chimera derived from strain 1-targeted ES
cells (typically strain 129) and a strain 2 mate (typically B6). F1, first generation offspring. F2, three
sets of second generation offspring that can be derived from intercrossing F1 animals. Strain
1-derived chromosomes carrying the targeted (-) or the wild-type (+) gene at the target locus
are shown in white. Homologous chromosomes from the second strain are shown in black; all carry
a wild-type gene (+) at the target locus. F2 progeny chromosomes are shown without centromeres
and telomeres to signify that crossovers reduce the extent of cosegregation to linked regions rather
than whole chromosomes.
their Ren loci from strain 129 (and there-
fore have four copies of a renin gene) have
higher blood pressures when fed 2% salt
than animals of the same proANP geno-
type that received three copies. These in
turn have pressures higher than the two-
copy animals that received both Ren loci
from B6 (John H. Krege and Simon W. M.
John, personal communication). These
preliminary experiments do not eliminate
the possibility that in this case the spreads
in phenotype are not in part or completely
due to strain differences in genes linked to
the Ren locus, but they do show how the
effects of segregation of a second chro-
mosomal region unlinked to the target
locus can be detected and how it can
influence the phenotype resulting from
the planned change at the target locus.
Effect of Genes Linked to the Target
Locus. Polymorphic differences in genes
linked to the target locus can cause more
serious complications. The frequency with
which related genes are linked to target
loci is much greater than would be ex-
pected by chance because related genes
often occur as linked clusters in the mam-
malian genome. For example, three
mouse apolipoprotein genes-Apoal,
Apoc3, andApoa4-are all within a 20-kb
stretch of DNA (unpublished data). Sim-
ilarly, two mouse natriuretic peptide pre-
cursor genes-proANP and proBNP-are
within 20 kb (Mark E. Steinhelper, per-
sonal communication).
Polymorphism in a related linked gene
is unimportant if the polymorphism has no
effect on the phenotype of interest. But
this will no longer be true if the linked
polymorphic allele affects the phenotype.
Imagine, for example, that strain 129 has
a linked polymorphic allele that affects the
phenotype under study positively when
compared to the corresponding allele in
strain B6. The effects of any negative
mutations at the target locus will in this
case be underestimated (or even reversed)
in a conventional comparison of F2 prog-
eny derived from intercrossing F1 het-
erozygotes. This is because all the F2
progeny that are homozygous mutant
(-/-) at the target locus will also be
homozygous for the strain 129-derived
(more positive) allele at the linked locus
(Fig. 4). Likewise all the F2 progeny from
this intercross that are wild type (+/+) at
the target locus will also be homozygous
for the B6-derived (less positive) allele at
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the linked locus. Thus, polymorphisms at
linked phenotype-related loci can alter the
apparent magnitude of the effects of the
targeting if only conventional F2 +/+,
+/-, and -/- progeny derived from
intercrossing F1 +/- animals are com-
pared. Conceivably, they could even re-
verse its sign, or give an apparent effect
from the targeting when none is there.
Linked genes will not, however, change
the spread of values within a specific tar-
get locus genotype.
In gene knockout experiments in which
the effects of absence of the target gene
product are extreme and overriding, com-
plications from linked strain differences
are usually of little concern (as in the case
of Apoe -/- mice). However, when the
phenotype is a quantitative variable and
the effects may be subtle, rigorous con-
trols in which the targeted mutation is the
sole variable become important. Fig. 4
illustrates some of the complexities intro-
duced by the use of two strains, even when
both are inbred. For example, the figure
illustrates that there are three classes (C,
D, and E) rather than one class of F2
wild-type animals. All are +/+ at the
target locus, but they differ in the sources
of their wild-type alleles. Likewise, there
are two classes (F and G) of mutant F2
heterozygote (+/-). Choice of rigorous
controls requires careful consideration of
these classes, as indicated in the legend to
Fig. 4. The different classes of F2 animals
can readily be distinguished if a natural
polymorphism can be found between the
two strains at the target locus. Otherwise,
it may be necessary to use simple sequence
length polymorphisms linked to the target
locus in order to identify them-a strategy
that was used in a related situation to
distinguish three-copy and four-copy F2
animals in our Agt gene experiments (26).
There are other ways of avoiding the
effects of strain differences in genes linked
to the target locus. For example, in the gene
titration experiment carried out at the Agt
locus, we compared the one-copy and three-
copy animals (26). The one-copy animals
and the three-copy animals both have a
wild-type Agt allele and nearby DNA de-
rived from strain B6, and both have a tar-
geted Agt allele and nearby DNA derived
from strain 129; they consequently differ
systematically only at the targeted locus.
This technical discussion is intended to
emphasize that, even in a complex genetic
system, gene targeting experiments can
with careful attention to details be de-
signed to prove that a specific phenotype
is caused by the targeted change and not
by any other differences between the par-
ticipating strains. This is the elusive proof
of causation referred to previously. Once
this proof has been secured, it may not be
necessary to continue to preserve the ge-
netic "purity" of a mutant strain. Alter-
natively, by backcrossing to an inbred
strain (such as B6) the genetic purity of a
targeted mutant can be recovered. The
resulting mutant strain will be inbred B6
except for being homozygous for a small
region derived from the ES cell strain that
includes and surrounds the target locus.
The complications associated with poly-
morphisms in genes closely linked to the
target loci therefore still remain, unless
backcrossing is also carried out to secure
animals having the ES cell-derived wild-
type gene at the target locus, but the
complications associated with polymor-
phisms elsewhere in the genome are elim-
inated. Consequently, when the effects of
combining targeted mutations at several
loci are to be investigated, animals back-
crossed to B6 (or any other chosen inbred
strain) are very valuable.
Conclusions
How are gene targeting experiments in
mice helping to develop a better under-
standing of the genetic etiologies of ath-
erosclerosis and essential hypertension,
and what can be expected from them in
the future?
At present, the most significant contri-
bution toward this understanding for ath-
erosclerosis is probably the generation of
precisely defined mouse models of the
disease: mice with disruption in the genes
coding for apoE or the LDL receptor.
These models are allowing assessment of
the effects of other genes on atherogenesis
by using the powerful genetic tools avail-
able in the mouse. Carefully controlled
investigations of the effects of diet or of
drugs are also facilitated by these animals.
At present, the most significant contribu-
tion to understanding the genetic etiology of
essential hypertension is probably the dem-
onstration that discrete alterations in the
expression of a variety of different genes can
individually cause changes in the blood pres-
sures of mice, even when the mice have all
their compensatory mechanisms intact.
These effects are readily detected in animals
having moderate decreases in gene function
due to heterozygosity for gene disruptions
or modest increases due to gene duplica-
tions.
Considerable work still remains to be
done in dissecting out in a rigorous man-
ner the effects of alterations in single
genes on the induction or progression of
atherosclerosis and on the control of
blood pressures. Perhaps even more excit-
ing is the opportunity now becoming avail-
able to breed animals in which the effects
of precise differences in more than one
gene can be studied in combination. It
would be overly optimistic to expect that
all data from the mouse will directly apply
to humans. Some species differences are
to be expected, but it will be important not
to dismiss unexpected findings too easily.
Indeed, determining the basis of the un-
expected findings with the help of mouse
genetics may provide important insights
into the causes and treatment of these
complex multifactorial diseases.
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